Vaccines aplenty

Current Opinion in Infectious Diseases

Volumn 15, Issue 5, 2002, Pages 461-463

  Halstead, Scott B ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIVAX; COMPLEMENTARY DNA; DEN 1 VACCINE; DEN 2 VACCINE; DEN 3 VACCINE; DEN 4 VACCINE; DENGUE VACCINE; ENCEPHALITIS VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; PDK 53; SA 14142; SA 14142 VACCINE; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS ENVELOPE PROTEIN; YELLOW FEVER VACCINE; VIRUS VACCINE;

CHIMERA; CLINICAL TRIAL; DENGUE; DRUG MARKETING; EDITORIAL; EPIDEMIC ENCEPHALITIS; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; JAPANESE ENCEPHALITIS VIRUS; LICENSING; NONHUMAN; PREVALENCE; SEROCONVERSION; TREATMENT OUTCOME; VACCINATION; VIRUS ATTENUATION; VIRUS ENVELOPE; VIRUS GENE; VIRUS TRANSMISSION; YELLOW FEVER; DENGUE VIRUS; GENETICS; IMMUNOLOGY;

DENGUE; DENGUE VIRUS; ENCEPHALITIS VIRUS, JAPANESE; ENCEPHALITIS, JAPANESE; HUMANS; VIRAL VACCINES;

EID: 0036790229     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200210000-00001     Document Type: Editorial

References (14)

1. Tsai TF. New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998. Vaccine 2000; 18 (suppl 2):1-25.
2. Halstead SB, Streit TG, Lafontant JG, et al. Haiti: absence of dengue hemorrhagic fever despite hyperendemic dengue virus transmission, Am J Trop Med Hyg 2001; 65:180-183.
3. Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science 1988; 239:476-481.
4. Halstead SB. Epidemiology of dengue and dengue hemorrhagic fever. In: Gubler DJ, Kuno G, editors. Dengue and dengue hemorrhagic fever. Wallingford, Oxon: CAB; 1997. pp. 23-44.
5. Bista MB, Banerjee MK, Shin SH, et al. Protection by a single dose of SA 14-14-2 live-attenuated Japanese encephalitis vaccine, Lancet 2002; 358:791-795.
6. Monath TP, McCarthy K, Bedford P, et al. Clinical proof of principle for ChimeriVax: recominant live, attenuated vaccines against flavivirus infections. Vaccine 2002; 20:1004-1018.
7. Guirakhoo F, Arroyo J, Pugachev KV, et al. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol 2001; 75:7290-7304.
8. Huang CY, Butrapet S, Pierro DJ, et al. Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine. J Virol 2000; 74:3020-3028.
9. Durbin AP, Karron RA, Sun W, et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. Am J Trop Med Hyg 2001; 65:405-413.
10. Markoff L, Pang X, Houng HS, et al. Derivation and characterization of a dengue type 1 host range-restricted mutant virus that is attenuated and highly immunogenic in monkeys. J Virol 2002; 76:3318-3328.
11. Bhamarapravati N, Yoksan S. Live attenuated tetravalent dengue vaccine. Vaccine 2000; 18:44-47.
12. Kanesa-thasan N, Sun W, Kim-Ahn G, et al. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 2001; 19:3179-3188.
13. Vaughn DW, Green S, Kalayanarooj S, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity, J Infect Dis 2000; 181:2-9.
14. He RT, Innis BL, Nisalak A, et al. Antibodies that block virus attachment to vero cells are a major component of the human neutralizing antibody response against dengue virus type 2. J Med Virol 1995; 45:451-461.